Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's interest expense for the
three
months ended in Mar. 2026 was E£ -130 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was E£-531 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Expense for the
three
months ended in Mar. 2026 was E£-130 Mil. Its
Operating Income
for the
three
months ended in Mar. 2026 was E£260 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2026 was E£72 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Interest Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Interest Expense Chart
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-531 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a Interest Expense of E£-531 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Interest Expense too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current Interest Expense is E£-531 Mil. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Interest Expense compare to ZTS and UTHR?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Interest Expense of E£-531 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Interest Expense is E£-531 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Modestly Overvalued. The stock's GF Value™ is E£4.09, compared to a current price of E£4.99 — trading 22% above its estimated fair value. The current Interest Expense is E£-531 Mil. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current Interest Expense is E£-531 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued.
The current stock price of E£4.99 is trading 22% above its estimated GF Value™ of E£4.09.
GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.
Key valuation signals for CAI:RMDA:
Interest Expense: E£-531 Mil
GF Value™: E£4.09 vs. price of E£4.99 (22% above fair value)
No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score
Get the complete analysis for CAI:RMDA
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:RMDA has been successfully added to your 
